Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling
Authors:
Open Access
- 28 December 2022
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-14
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive disorder that causes airway obstruction and lung inflammation. The first-line treatment of COPD is the bronchodilators of β2-agonists and antimuscarinic drugs, which can help control the airway obstruction, but the long-term use might render the drug tolerance. Bisphosphonates are widely used in osteoclast-mediated bone diseases treatment for decades. For drug repurposing, can delivery of a third generation of nitrogen-containing bisphosphonate, risedronate (RIS) ameliorate the progression of COPD? Methods: COPD rats or mice models have been established through cigarette-smoking and elastase injection, and then the animals are received RIS treatment via nebulization. Lung deposition of RIS was primarily assessed by high-performance liquid chromatography (HPLC). The respiratory parameters of airway obstruction in COPD rats and mice were documented using plethysmography method and resistance-compliance system. Results: High lung deposition and bioavailability of RIS was monitored with 88.8% of RIS input dose. We found that RIS could rescue the lung function decline of airspace enlargement and mean linear intercept in the COPD lung. RIS could curb the airway obstruction by suppressing 60% of the respiratory resistance and elevating the airway’s dynamic compliance, tidal volume and mid-expiratory flow. As an inhibitor of farnesyl diphosphate synthase (FDPS), RIS suppresses FDPS-mediated RAS and RhoA prenylation to obstruct its membrane localization in airway smooth muscle cells (ASMCs), leading to the inhibition of downstream ERK-MLCK and ROCK1-MLCP pathway to cause ASMCs relaxation. Additionally, RIS nebulization impeded pro-inflammatory cell accumulation, particularly macrophages infiltration in alveolar parenchyma. The NF-κB, tumor necrosis factor-alpha, IL-1β, IL-8, and IL-6 declined in microphages following RIS nebulization. Surprisingly, nebulization of RIS could overcome the tolerance of β2-agonists in COPD-rats by increasing the expression of β2 receptors. Conclusions: Nebulization of RIS could alleviate airway obstruction and lung inflammation in COPD, providing a novel strategy for treating COPD patients, even those with β2-agonists tolerance.Keywords
This publication has 36 references indexed in Scilit:
- Cell separation: Terminology and practical considerationsJournal of Tissue Engineering, 2012
- The Salmonella Kinase SteC Targets the MAP Kinase MEK to Regulate the Host Actin CytoskeletonCell Host & Microbe, 2012
- A novel EST‐derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2‐adrenergic receptor internalization and down‐regulationThe FASEB Journal, 2012
- Cigarette smoke-induced emphysema in A/J mice is associated with pulmonary oxidative stress, apoptosis of lung cells, and global alterations in gene expressionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Myosin phosphatase target subunit: Many roles in cell functionBiochemical and Biophysical Research Communications, 2008
- Targeting by myosin phosphatase‐RhoA interacting protein mediates RhoA/ROCK regulation of myosin phosphataseJournal of Cellular Biochemistry, 2007
- SIGNALING FOR CONTRACTION AND RELAXATION IN SMOOTH MUSCLE OF THE GUTAnnual Review of Physiology, 2006
- MAP kinases and cell migrationJournal of Cell Science, 2004
- Synthetic responses in airway smooth muscleJournal of Allergy and Clinical Immunology, 2004
- Appraisal of four pre-column derivatization methods for the high-performance liquid chromatographic determination of free amino acids in biological materialsJournal of Chromatography A, 1990